RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BOTTINI A
Collezione AOU San Luigi di Orbassano

Items : 12

Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Dec 1;32(34):3883-91. doi: 10.1200/JCO.2014.55.2836. Epub 2014 Oct 27.

2014
AOU San Luigi di Orbassano

Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP;

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). in Journal of the National Cancer Institute. Monographs / J Natl Cancer Inst Monogr. 2011;2011(43):147-51. doi: 10.1093/jncimonographs/lgr037.

2011
AOU San Luigi di Orbassano

Berruti A; Generali D; Kaufmann M; Puztai L; Curigliano G; Aglietta M; Gianni L; Miller WR; Untch M; Sotiriou C; Daidone M; Conte P; Kennedy D; Damia G; Petronini P; Di Cosimo S; Bruzzi P; Dowsett M; Desmedt C; Mansel RE; Olivetti L; Tondini C; Sapino A; Fenaroli P; Tortora G; Thorne H; Bertolini F; Ferrozzi F; Danova M; et alii...

Intermediate endpoints of primary systemic therapy in breast cancer patients. in Journal of the National Cancer Institute. Monographs / J Natl Cancer Inst Monogr. 2011;2011(43):142-6. doi: 10.1093/jncimonographs/lgr036.

2011
AOU San Luigi di Orbassano

Berruti A; Generali D; Bertaglia V; Brizzi MP; Mele T; Dogliotti L; Bruzzi P; Bottini A;

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. in Breast cancer research and treatment / Breast Cancer Res Treat. 2010 Oct;123(3):795-804. doi: 10.1007/s10549-010-1063-0. Epub 2010 Aug 3.

2010
AOU San Luigi di Orbassano

Mele T; Generali D; Fox S; Brizzi MP; Bersiga A; Milani M; Allevi G; Bonardi S; Aguggini S; Volante M; Dogliotti L; Bottini A; Harris A; Berruti A;

Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. in The oncologist / Oncologist. 2008 Nov;13(11):1137-48. doi: 10.1634/theoncologist.2008-0162. Epub 2008 Nov 7.

2008
AOU San Luigi di Orbassano

Berruti A; Brizzi MP; Generali D; Ardine M; Dogliotti L; Bruzzi P; Bottini A;

Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. in Breast cancer research and treatment / Breast Cancer Res Treat. 2006 Aug;98(3):241-8. doi: 10.1007/s10549-005-9155-y. Epub 2006 May 3.

2006
AOU San Luigi di Orbassano

Tampellini M; Berruti A; Bitossi R; Gorzegno G; Alabiso I; Bottini A; Farris A; Donadio M; Sarobba MG; Manzin E; Durando A; Defabiani E; De Matteis A; Ardine M; Castiglione F; Danese S; Bertone E; Alabiso O; Massobrio M; Dogliotti L;

Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. in Endocrine-related cancer / Endocr Relat Cancer. 2005 Jun;12(2):383-92. doi: 10.1677/erc.1.00945.

2005
AOU San Luigi di Orbassano

Bottini A; Berruti A; Brizzi MP; Bersiga A; Generali D; Allevi G; Aguggini S; Bolsi G; Bonardi S; Tondelli B; Vana F; Tampellini M; Alquati P; Dogliotti L;

Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2005 Jan;41(2):249-55. doi: 10.1016/j.ejca.2004.07.003.

2005
AOU San Luigi di Orbassano

Berruti A; Bitossi R; Bottini A; Bonardi S; Donadio M; Nigro C; Bertetto O; Danese S; Bertone E; Sarobba MG; Farris A; Katsaros D; Castiglione F; Volpe T; Lattuada S; Mancarella S; Dogliotti L;

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. in British journal of cancer / Br J Cancer. 2005 Feb 28;92(4):634-8. doi: 10.1038/sj.bjc.6602335.

2005
AOU San Luigi di Orbassano

Berruti A; Bitossi R; Gorzegno G; Bottini A; Generali D; Milani M; Katsaros D; Rigault de la Longrais IA; Bellino R; Donadio M; Ardine M; Bertetto O; Danese S; Sarobba MG; Farris A; Lorusso V; Dogliotti L;

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2002 Oct 15;20(20):4150-9. doi: 10.1200/JCO.2002.08.012.

2002
AOU San Luigi di Orbassano

Berruti A; Bitossi R; Gorzegno G; Bottini A; Alquati P; De Matteis A; Nuzzo F; Giardina G; Danese S; De Lena M; Lorusso V; Farris A; Sarobba MG; DeFabiani E; Bonazzi G; Castiglione F; Bumma C; Moro G; Bruzzi P; Dogliotti L;

Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine / Tumour Biol. 2001 Nov-Dec;22(6):367-73. doi: 10.1159/000050639.

2001
AOU San Luigi di Orbassano

Tampellini M; Berruti A; Gorzegno G; Bitossi R; Bottini A; Durando A; De Matteis A; Farris A; Donadio M; De Fabiani E; Manzin E; Arese P; Sarobba MG; Castiglione F; Moro G; Bonazzi G; Nuzzo F; Massobrio M; Dogliotti L;

Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study. in Cancer chemotherapy and pharmacology / Cancer Chemother Pharmacol. 1998;41(4):333-8. doi: 10.1007/s002800050747.

1998
AOU San Luigi di Orbassano

Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G;